Section Arrow
ABVX.NASDAQ
- Abivax SA
Quotes are at least 15-min delayed:2025/11/04 07:40 EST
Pre Market
Last
 97.55
-1.3 (-1.32%)
Bid
97.44
Ask
97.7
High 98.85 
Low 95.95 
Volume 23351 
Regular Hours
Last
 98.85
-3.57 (-3.49%)
Day High 
101.89 
Prev. Close
102.42 
1-M High
108 
Volume 
1.96M 
Bid
97.44
Ask
97.7
Day Low
96.52 
Open
101.4 
1-M Low
81.9 
Market Cap 
7.97B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 94.98 
20-SMA 93.46 
50-SMA 87.31 
52-W High 108 
52-W Low 4.77 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.09/-2.31
Enterprise Value
8.02B
Balance Sheet
Book Value Per Share
-0.72
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PHIOPhio Pharmaceuticals Corp1.86-0.19-9.27%0.01PE
Pre Market 1.7 -0.16 -8.60%
CRBUCaribou Biosciences2.43+0.01+0.41%-- 
Pre Market 2.42 -0.01 -0.41%
IOVAIovance Biotherapeutics1.95-0.02-1.02%-- 
Pre Market 1.91 -0.04 -2.05%
RXRXRecursion Pharmaceuticals5.44-0.08-1.45%-- 
Pre Market 5.25 -0.19 -3.49%
THARTharimmune Inc.3.2+0.25+8.47%0.03PE
Pre Market 3.01 -0.19 -5.94%
Quotes are at least 15-min delayed:2025/11/04 07:40 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.